LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited has raised A$10.5 million through a share placement, surpassing investor demand, to fast-track the commercialization of SPONTAN®, their innovative nasal spray for erectile dysfunction (ED). The funds will enhance regulatory processes, research and development, and sales initiatives, signaling a swift move to make SPONTAN® available via Australia’s Special Access Scheme. The company is also exploring partnerships to launch the product globally in the burgeoning ED market, aiming to overcome current treatment limitations and meet the anticipated demand.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
